SWM
TEVA icon

Sugarloaf Wealth Management’s Teva Pharmaceuticals TEVA Stock Holding History

Sugarloaf Wealth Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-58
Closed -$818 – 684
2024
Q1 		$818 Buy
+58
New +$731 ﹤0.01% 631

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sugarloaf Wealth Management's TEVA Position: Q2 2024 in Review

Sugarloaf Wealth Management sold out of Teva Pharmaceuticals (TEVA) in Q2 2024, closing a stake of 58 shares — an estimated $818 sold.

Sugarloaf Wealth Management first reported a position in TEVA in Q1 2024 and held it in 1 quarter. The position peaked at $818 in Q1 2024. 533 funds tracked by Wall St. Rank hold TEVA as of Q2 2024.

  • Sugarloaf Wealth Management reported no remaining Teva Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Sugarloaf Wealth Management sold 58 Teva Pharmaceuticals shares in Q2 2024, an estimated $818.
  • Sugarloaf Wealth Management first reported a position in Teva Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • Sugarloaf Wealth Management's Teva Pharmaceuticals position peaked at $818 in Q1 2024.
  • 533 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2024.

Based on Sugarloaf Wealth Management's 13F filing for Q2 2024, filed 8 Jul 2024.